Phathom Pharmaceuticals (PHAT) Depreciation & Amortization (CF) (2019 - 2026)

Phathom Pharmaceuticals (PHAT) has 8 years of Depreciation & Amortization (CF) data on file, last reported at $110000.0 in Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 37.85% year-over-year to $110000.0 in Q1 2026; TTM through Mar 2026 was $566000.0, a 25.33% decrease from a year earlier, with the FY2025 full-year figure at $633000.0, down 20.38% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $110000.0, down from $128000.0 in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for PHAT reached as high as $214000.0 in Q1 2024 and fell as low as $110000.0 in Q1 2026.
• Historically, Depreciation & Amortization (CF) has averaged $160764.7 across 5 years, with a median of $168000.0 in 2022.
• Across the five-year window, Depreciation & Amortization (CF) jumped 60.16% in 2024 and slumped 37.85% in 2026, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $168000.0 in 2022, then grew by 10.12% to $185000.0 in 2023, then increased by 4.32% to $193000.0 in 2024, then sank by 33.68% to $128000.0 in 2025, then dropped by 14.06% to $110000.0 in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $110000.0 in Q1 2026, $128000.0 in Q4 2025, and $156000.0 in Q3 2025.